[The use of glucuronyl glucosamine glycan sulfate in dyslipidemic subjects with labyrinth disease].
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy*; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D007759:Labyrinth Diseases / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014012:Tinnitus / Q000188:drug therapy; D014717:Vertigo / Q000188:drug therapy
D006025:Glycosaminoglycans; C007858:glucuronyl glucosamine glycan sulfate
L'impiego del glucuronilglucosaminoglicano-solfato in soggetti dislipidemici con sofferenza labirintica.